P.6.083 Enhanced striatal dopamine transporter activity in drug naive and previously treated patients with gilles de la tourette syndrome (GTS): A [123l]-β-CIT SPECT-study

1997 ◽  
Vol 7 ◽  
pp. S289-S290
Author(s):  
M. Stamenkovic ◽  
S.D. Schindler ◽  
S. Asenbaum ◽  
Th. Brücke ◽  
H.N. Aschauer ◽  
...  
Keyword(s):  
Dopamine Transporter ◽  
Tourette Syndrome ◽  
Striatal Dopamine ◽  
Previously Treated Patients ◽  
Previously Treated ◽  
Drug Naïve

scholarly journals The striatal dopamine transporter in first-episode, drug-naive schizophrenic patients: evaluation by the new SPECT-ligand[99mTc]TRODAT-1

2005 ◽  
Vol 19 (5) ◽  
pp. 488-493 ◽  
Author(s):  
G. J. E Schmitt ◽  
E. M. Meisenzahl ◽  
T. Frodl ◽  
C. La Fougère ◽  
K. Hahn ◽  
...  
Keyword(s):  
Dopamine Transporter ◽  
Striatal Dopamine ◽  
First Episode ◽  
Schizophrenic Patients ◽  
Drug Naïve

Clinical and Striatal Dopamine Transporter Predictors of Mild Behavioral Impairment in Drug-Naive Parkinson Disease

2020 ◽  
Vol 45 (11) ◽  
pp. e463-e468 ◽  
Author(s):  
Han Soo Yoo ◽  
Sangwon Lee ◽  
Seok Jong Chung ◽  
Byoung Seok Ye ◽  
Young H. Sohn ◽  
...  
Keyword(s):  
Parkinson Disease ◽  
Dopamine Transporter ◽  
Striatal Dopamine ◽  
Behavioral Impairment ◽  
Drug Naïve

Striatal dopamine transporter density in drug naive patients with attention-deficit/hyperactivity disorder

2006 ◽  
Vol 27 (3) ◽  
pp. 267-270 ◽  
Author(s):  
Rolf Larisch ◽  
Wolfgang Sitte ◽  
Christina Antke ◽  
Susanne Nikolaus ◽  
Matthias Franz ◽  
...  
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Dopamine Transporter ◽  
Attention Deficit ◽  
Striatal Dopamine ◽  
Hyperactivity Disorder ◽  
Drug Naïve

A Multicenter Pharmacosurveillance Study for the Evaluation of the Efficacy and Safety of Recombinant Factor VIII in the Treatment of Patients with Hemophilia A

1997 ◽  
Vol 78 (05) ◽  
pp. 1352-1356 ◽  
Author(s):  
Emel Aygören-Pürsün ◽  
Inge Scharrer ◽  
Keyword(s):  
Factor Viii ◽  
Hemophilia A ◽  
Parvovirus B19 ◽  
Subjective Evaluation ◽  
Recombinant Factor Viii ◽  
Fviii Inhibitor ◽  
Previously Treated Patients ◽  
Previously Treated ◽  
Bleeding Episodes ◽  
Recombinant Fviii

SummaryIn this open multicenter study the safety and efficacy of recombinant factor VIII (rFVIII) was assessed in 39 previously treated patients with hemophilia A (factor VIII basal activity ≤15%).Recombinant FVIII was administered for prophylaxis and treatment of bleeding episodes and for surgical procedures. A total of 3679 infusions of rFVIII were given. Efficacy of rFVIII as assessed by subjective evaluation of response to infusion and mean annual consumption of rFVIII was comparable to that of plasma derived FVIII concentrates. The incremental recovery of FVIII (2.4 ± 0,83%/IU/kg, 2.12 ± 0.61%/IU/kg, resp.) was within the expected range. No clinical significant FVIII inhibitor was detected in this trial. Five of 16 susceptible patients showed a seroconversion for parvovirus B19. However, the results are ambiguous in two cases and might be explained otherwise in one further case. Thus, in two patients a reliable seroconversion for parvovirus B19 was observed.

Sign in / Sign up

Export Citation Format

Share Document